Rabbit Polyclonal METTL13 antibody. C-terminal. Suitable for WB and reacts with Human, Mouse samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human METTL13 aa 600 to C-terminus.
pH: 7 - 8
Preservative: 0.09% Sodium azide
Constituents: 99% Tris citrate/phosphate
WB | |
---|---|
Human | Tested |
Mouse | Tested |
Rat | Predicted |
Chimpanzee | Predicted |
Dog | Predicted |
Gorilla | Predicted |
Horse | Predicted |
Orangutan | Predicted |
Pig | Predicted |
Rabbit | Predicted |
Rhesus monkey | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500.00000 - 1/2500.00000 | Notes - |
Species Mouse | Dilution info 1/500.00000 - 1/2500.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Rabbit, Horse, Dog, Pig, Chimpanzee, Rhesus monkey, Gorilla, Orangutan | Dilution info - | Notes - |
Select an associated product type
Dual methyltransferase that catalyzes methylation of elongation factor 1-alpha (EEF1A1 and EEF1A2) at two different positions, and is therefore involved in the regulation of mRNA translation (PubMed:30143613, PubMed:30612740). Via its C-terminus, methylates EEF1A1 and EEF1A2 at the N-terminal residue 'Gly-2' (PubMed:30143613). Via its N-terminus dimethylates EEF1A1 and EEF1A2 at residue 'Lys-55' (PubMed:30143613, PubMed:30612740). Has no activity towards core histones H2A, H2B, H3 and H4 (PubMed:30612740).
EEF1AKNMT, FEAT, KIAA0859, CGI-01, METTL13, eEF1A lysine and N-terminal methyltransferase, eEF1A-KNMT, Methyltransferase-like protein 13
Rabbit Polyclonal METTL13 antibody. C-terminal. Suitable for WB and reacts with Human, Mouse samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human METTL13 aa 600 to C-terminus.
pH: 7 - 8
Preservative: 0.09% Sodium azide
Constituents: 99% Tris citrate/phosphate
ab186008 was affinity purified using an epitope specific to METTL13 immobilized on solid support.
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
METTL13 also known as METTL13-NAT2 is a methyltransferase enzyme that plays a mechanical role in protein synthesis through methylation. It transfers methyl groups particularly at the N-terminus of elongation factor 1A (eEF1A) which is essential for its activity. The molecular weight of METTL13 is approximately 64 kDa. This enzyme is expressed in various tissues with significant levels observed in the liver heart and skeletal muscle indicating an important role in bodily metabolic processes.
METTL13 is highly involved in the regulation of protein translation. By methylating the elongation factor eEF1A METTL13 influences protein synthesis at the ribosome ensuring the proper function and fidelity of translation. METTL13 is a part of the broader group of methyltransferases which are enzymes that modify proteins and other biomolecules by adding methyl groups impacting gene expression and cellular processes.
METTL13 integrates into translational control and signaling pathways. One of the key pathways including METTL13 is the mTOR signaling pathway which governs cell growth and metabolism through protein synthesis. METTL13 interacts with proteins within this pathway such as eEF2K influencing translation and cellular metabolism. In the context of cell signaling METTL13 contributes to gene expression modulation impacting cellular responses to environmental signals.
METTL13 has been linked to cancer and metabolic disorders. Studies reveal an association between aberrant METTL13 expression and tumor growth suggesting a role in oncogenesis through the modification of protein synthesis and cellular proliferation pathways. Additionally METTL13 might influence metabolic disorders by affecting the proteins involved in cellular metabolic regulation. The interplay between METTL13 and proteins like eEF1A highlights the complexity in disease progression and potential therapeutic targeting.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-METTL13 antibody - C-terminal (ab186008) at 1 µg/mL
Lane 1: HeLa whole cell lysate at 50 µg
Lane 2: 293T whole cell lysate at 50 µg
Lane 3: Jurkat whole cell lysate at 50 µg
Lane 4: TCMK whole cell lysate at 50 µg
Lane 5: 3T3 whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 79 kDa
Exposure time: 3min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com